Semaglutide reduces risk of major adverse cardiovascular events in adults with overweight or obesity
People living with overweight or obesity are 20 per cent less likely to develop heart problems if they are treated with once-weekly semaglutide 2.4 mg, latest research suggests. Novo Nordisk has ...